{'fraction_non_alphanumeric': 0.027347310847766638, 'fraction_numerical': 0.0036463081130355514, 'mean_word_length': 5.0, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The role of ifosfamide in germ cell tumors and small cell lung cancer.

Ifosfamide has been found to have antineoplastic activity in a variety of solid tumors. In germ cell tumors, the substitution of ifosfamide for bleomycin in the standard combination bleomycin/etoposide/cisplatin (BEP) did not improve efficacy and caused significantly more toxicity than BEP. This regimen (VIP), however, has shown promise when used with high-dose carboplatin/etoposide as salvage therapy in patients with germ cell tumors not responding to first-line BEP. It is unclear whether the addition of ifosfamide to the carboplatin/etoposide regimen results in an improved therapeutic outcome in patients with multiple recurrent germ cell tumors. In such patients, as well as in those with poor-risk germ cell cancer, high-dose chemotherapy given with hematopoietic growth factors and bone marrow rescue may have a role. In small cell lung cancer, single-agent ifosfamide has produced response rates of 48% to 76%. Currently, the role of ifosfamide is being defined in untreated and recurrent small cell lung cancer.